Ocuphire Pharma is clinical stage biopharmaceutical company developing therapies to improve patient outcomes in cancers. Co.'s pipeline features two oncology product candidates in clinical development and additional compounds in pre-clinical development. Co.'s drug candidates are: RX-3117, which is an investigational oral small molecule nucleoside compound that provides the potential for a targeted anti-cancer therapy; RX-5902, which is a small molecule modulator that modulates the pathway via inhibition of phosphorylated p68 which hinders the transport of beta-catenin into the nucleus and reduces the activation of cancer genes; and RX-0301, which is a potential potent inhibitor. The OCUP stock yearly return is shown above.
The yearly return on the OCUP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OCUP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|